Insider Selling: Zura Bio Limited (NASDAQ:ZURA) Director Sells 1,001,633 Shares of Stock

Zura Bio Limited (NASDAQ:ZURA) Director Parvinder Thiara sold 1,001,633 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Zura Bio Price Performance

Shares of Zura Bio stock traded down $0.01 during trading hours on Wednesday, hitting $3.00. 228,283 shares of the company were exchanged, compared to its average volume of 327,384. Zura Bio Limited has a 1 year low of $2.00 and a 1 year high of $6.35. The business has a 50-day moving average of $4.12 and a 200-day moving average of $4.03.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Equities analysts predict that Zura Bio Limited will post -0.65 earnings per share for the current year.

Institutional Trading of Zura Bio

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC lifted its position in Zura Bio by 51.3% during the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after buying an additional 5,900 shares during the period. Bank of New York Mellon Corp boosted its position in Zura Bio by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after buying an additional 6,412 shares during the last quarter. Forefront Analytics LLC increased its stake in shares of Zura Bio by 22.1% in the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock worth $145,000 after buying an additional 7,531 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Zura Bio during the 3rd quarter worth approximately $46,000. Finally, AQR Capital Management LLC bought a new position in shares of Zura Bio in the 2nd quarter worth about $43,000. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Leerink Partners started coverage on shares of Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 price target on the stock. Leerink Partnrs upgraded Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. Piper Sandler reiterated an “overweight” rating and issued a $26.00 price objective on shares of Zura Bio in a research report on Thursday, September 19th. Chardan Capital lowered their price objective on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 8th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a report on Monday, November 18th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $15.80.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.